Healthcare is entering a critical phase regarding the integration of artificial intelligence (AI), as evidenced by discussions at HIMSS26, held recently. The focus has shifted from the potential of AI to pressing questions of scalability, governance, and cultural sustainability. Instead of celebrating high-profile product launches, stakeholders confronted the uncomfortable realities that are impeding meaningful transformation, including execution gaps, consumer accountability, and organizational inertia.
As the industry grapples with escalating costs and tighter coverage dynamics, the conversations at HIMSS26 increasingly emphasized the importance of AI’s operational value. Vendors and speakers underscored that AI must now demonstrate its effectiveness not just in incremental productivity improvements but as an integral part of existing workflows. For instance, Epic unveiled its Agent Factory, designed to enable health systems to develop, implement, and monitor AI agents directly within electronic health records (EHRs). Similarly, Microsoft expanded its Dragon Copilot into a more comprehensive platform that integrates clinical, operational, and revenue cycle intelligence across various partner ecosystems.
Another prominent theme was the rise of agentic AI, particularly for back-office functions. The narrative surrounding AI has shifted from being a supportive tool—like copilots—to becoming autonomous agents capable of executing tasks with minimal human intervention. Platforms like FinThrive’s Fusion and Innovaccer’s Flow Capture are positioning AI as an operational model rather than merely a feature. Early adopters of these technologies report tangible benefits, such as revenue recovery and enhanced coding capacity.
However, the discussions also highlighted governance and security as significant barriers to scaling AI solutions. As the capabilities of agentic AI expand, governance frameworks lag behind. Concerns were raised about accountability, decision-making transparency, and the need for ongoing monitoring of AI systems in real-world clinical and financial environments. Many healthcare organizations (HCOs) are deploying AI solutions faster than they can validate or oversee them, raising alarms about operational safety and compliance.
Financial pressures are driving the healthcare sector’s renewed focus on revenue cycle management (RCM) tools, where AI applications are seen as aligned with urgent board-level priorities. With increasing complexity in patient benefits and responsibilities, leaders are beginning to view financial experiences as inextricably linked to patient access and health outcomes. AI-driven initiatives aimed at improving payment integrity, automating prior authorizations, and enhancing patient financial communications consistently emerged as promising areas for measurable return on investment.
Yet, critical aspects of an effective technology strategy appear to have been overlooked during the event. Notably absent were discussions around consumer engagement, regulatory accountability, and workforce implications of advancing AI technologies. While the consumer experience was a frequent topic, accountability for ensuring transparency and affordability was rarely addressed. HCO leaders need to articulate who is responsible for empowering consumers along fragmented healthcare journeys.
Moreover, while many leaders privately acknowledged that regulatory complexities are stymying innovation, public sessions largely skirted the topic. Changes in payer rules, ambiguities surrounding AI oversight, and compliance uncertainties are contributing to stalled initiatives, yet few leaders offered concrete strategies for adapting to this environment. The tension between risk aversion and the need for adaptive execution was palpable among attendees.
Concerns about workforce disruption due to agentic AI also went largely unaddressed. While vendors highlighted the efficiency gains from AI, little focus was given to the need for role redesign, training, and trust-building in hybrid human-agent environments. The rapid deployment of AI technologies raises questions about long-term adoption and safety, particularly regarding validation, clinician involvement, and patient testing.
Shared accountability for security was another vague area, despite many HCO leaders citing it as a priority. As vendors gain broader access to clinical and financial systems, HCOs are demanding clearer contractual accountability and auditability—a need that few vendors seem prepared to meet adequately.
Healthcare leaders are urged to concentrate on several key operational areas. First, execution capability must become the differentiating factor, as most HCOs now have access to similar AI tools and vendors. The advantage will come from executing these technologies effectively rather than being the first to adopt them. Leaders should focus on standardizing workflows and maintaining performance to outpace competitors still mired in pilot projects.
Furthermore, predictability—not novelty—will drive consumer trust. The absence of clear accountability for consumer empowerment indicates that many HCOs confuse engagement with genuine progress. Consumers increasingly seek reduced unpredictability in costs and access, urging HCOs to treat AI and digital strategies as reliability challenges rather than mere experience design issues.
Lastly, as financial pressures shape the future landscape, AI initiatives that can demonstrate measurable operational impacts will likely receive continued backing. Projects that focus on reducing friction, preventing revenue leakage, or improving cash flow will thrive, while those tied solely to long-term transformation goals may struggle to secure support. In this evolving environment, capital investment is likely to follow tangible results rather than visionary promises.
